Abstract 670P
Background
DLL3 is expressed on many cancers, including small-cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinomas (epNECs), and large cell neuroendocrine carcinoma of the lung (LCNEC). BI 764532 is a DLL3/CD3 IgG-like T cell engager that initiates T cell-mediated immune responses against DLL3+ tumors. NCT04429087 is a Phase I trial of BI 764532 in pts with DLL3+ SCLC, epNECs or LCNEC.
Methods
Escalating doses of BI 764532 were given IV in 4 regimens: RA (fixed dose q3w); RB1 (fixed dose qw); RB2 and RB3 (step-in dose, then target dose). Treatment (Tx) continued until progression, unacceptable toxicity, other withdrawal criteria, or for 36 months (mos) maximum. Primary objective: determine MTD and/or RDE of BI 764532. Other objectives: safety; tolerability; PK/PD; preliminary efficacy (investigator-assessed; RECIST 1.1).
Results
As of Feb 21, 2024, 168 pts had ≥1 dose of BI 764532 (RA: n=24; RB1: n=10; RB2: n=79; RB3: n=55). Median age: 61 yrs (range 32–81); ECOG PS 0/1/missing: 27/67/5%; prior PD1/PD-L1 Tx: 51%; ≥2 prior lines of Tx: 72%. SCLC/epNEC/LCNEC: 49/42/8%. 6 pts experienced DLTs during the MTD evaluation period (all on RB2): G4 CRS; G3 CRS; G5 ICANS; G3 ICANS; G3 nervous system disorder; G2 infusion-related reaction). MTD was not reached. TRAEs (any/G3+): overall 88/24%; RA 79/21%; RB1 60/20%; RB2 96/34%; RB3 86/11%. Most common TRAEs were (any/G3+): CRS (57/3%); dysgeusia (23/0%); pyrexia (21/0%); asthenia (20/1%). With RB2/RB3, most CRS and neurological events occurred early, and were reversible. Unconfirmed tumor response data are shown below. Efficacy was highest with RB2/RB3 where all pts received target doses of ≥90 μg/kg. Overall, median DoR (95% CI): 8.5 mos (6.2—NR); estimated 6-mo DoR: 70%. 23/38 responding pts are still on Tx. Median PFS (95% CI): 1.5 mos (1.4-2.4); estimated 6-mo PFS: 20%.
Conclusions
BI 764532 showed clinically manageable tolerability and promising efficacy in SCLC, epNEC and LCNEC. Table: 670P
SCLC ORR/DCR, % | n | epNEC ORR/DCR, % | n | LCNEC ORR/DCR, % | n | All ORR/DCR, % | n | |
RA | 7/20 | 15 | 14/29 | 7 | 0/50 | 2 | 8/25 | 24 |
RB1 | 0/0 | 4 | 0/20 | 5 | 0/0 | 1 | 0/10 | 10 |
RB2 | 22/44 | 41 | 22/41 | 32 | 83/100 | 6 | 27/47 | 79 |
RB3† | 20/40 | 20 | 31/50 | 26 | 50/75 | 4 | 29/49 | 51 |
Total | 18/36 | 80 | 23/41 | 70 | 54/77 | 13 | 23/42 | 164* |
*Assessable pts started Tx ≥7 wks prior to data cut-off; †tumor type missing in one patient
Clinical trial identification
NCT04429087.
Editorial acknowledgement
Medical writing support for the development of this abstract was provided by Lynn Pritchard, DPhil, of Ashfield MedComms.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
M. Wermke: Financial Interests, Personal, Other, Honoraria: Amgen, Boehringer Ingelheim, Eli Lilly, GWT, Janssen, Merck Serono, Novartis, Synlab; Financial Interests, Personal, Other, Travel/accommodation/expenses: Amgen, AstraZeneca, Bristol Myers Squibb, GEMoaB, Immatics, Merck Serono, Pfizer, Sanofi/Aventis; Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, ImCheck Therapeutics, Immatics, ISA Pharmaceuticals, Novartis. V. Gambardella: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Genentech, Merck Serono, Roche, Beigen, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Natera, Sierra Oncology, AstraZeneca, Medimmune, BMS, MSD; Financial Interests, Personal, Research Funding: Bayer, Boehringer Ingelheim, Roche. Y. Kuboki: Financial Interests, Personal, Advisory Board: Amgen, Boehringer Ingelheim, Takeda, Incyte, Abbie; Financial Interests, Personal, Other, Honoraria: Eli Lilly Japan, Taiho Pharmaceutical, Takeda; Financial Interests, Institutional, Research Funding: AbbVie, Amgen, Astellas Pharma, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Genmab, Incyte, Ono Pharmaceutical, Taiho Pharmaceutica, Takeda, AstraZeneca, Merck, Novartis, Hengrui. E. Felip: Financial Interests, Personal, Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Genmab, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point, Daiichi Sankyo; Financial Interests, Personal, Other, independent member of the board: Grifols; Financial Interests, Personal, Speaker’s Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Peervoice, Pfizer, Sanofi, Takeda, Touch Oncology. M.F. Sanmamed: Non-Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Numab; Financial Interests, Personal, Royalties: MSD. O. Alese: Financial Interests, Personal, Advisory Board: Ipsen Pharmaceuticals, Aadi Bioscience, Taiho, Pfizer, Seagen Inc., Bristol Myers Squibb, AstraZeneca, Exelixis, Takeda; Financial Interests, Institutional, Research Grant: Taiho Oncology, Ipsen Pharmaceuticals, GSK, Bristol Myers Squibb, Suzhou Transcenta Therapeutics Co. Ltd., Boehringer Ingelheim, Cue Biopharma, Inc., Merck, Inhibitex Inc, Arcus Biosciences Inc. C.M. Sayehli: Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim; Financial Interests, Personal, Other, Travel/accommodation/expenses: Boehringer Ingelheim, Catalym, Eli Lilly, Ipsen Pharma. E. Arriola Aperribay: Financial Interests, Personal, Other, Honoraria: Takeda, Lilly, Roche, Boehringer Ingelheim, Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal, Other, Travel/accommodation/expenses: Takeda, Roche, MSD, AstraZeneca; Financial Interests, Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Lilly, Roche, MSD, Boehringer Ingelheim, BMS, AstraZeneca. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, Merck, Mirati, MSD (Merck Sharp & Dohme), Novartis, Nuvalent, Pfizer, Roche, Seattle Genetic, Takeda, Turning Point; Financial Interests, Institutional, Research Funding: BMS, Janssen, Novartis, Pfizer, AstraZeneca. L. Villaruz: Financial Interests, Personal, Advisory Board: Sanofi, Gilead, Johnson and Johnson, Daiichi Sankyo, AstraZeneca; Financial Interests, Personal, Advisory Role: EMD Serono. M. Studeny, M. Bouzaggou, X. Fang: Financial Interests, Personal, Full or part-time Employment: Boehringer Ingelheim. D. Morgensztern: Financial Interests, Personal, Advisory Board: AbbVie, Eli Lilly, Arcus, Mirati; Financial Interests, Personal, Advisory Role: Arcus; Financial Interests, Personal, Principal Investigator: AbbVie, Arcus, Merck, Novartis, Pfizer, Bristol Myers Squibb, Incyte, Surface, Amgen, Genprex, Boehringer Ingelheim, NeoImmunotech, Apollomics.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01